Latest News of LBC
There's A Lot To Like About Plumas Bancorp's (NASDAQ:PLBC) Upcoming US$0.27 Dividend
By Yahoo! Finance |
2 weeks ago
Investors eyeing Plumas Bancorp (NASDAQ:PLBC) for its dividend should act soon, as the stock is going ex-dividend. The company's next payment will be US$0.27 per share, with a trailing yield of 2.7%....
Institutions own 40% of Plumas Bancorp (NASDAQ:PLBC) shares but retail investors control 48% of the company
By Yahoo! Finance |
1 month ago
Retail investors own 48% of Plumas Bancorp stock, while institutions hold 40%. Major institutional shareholders include FMR LLC, BlackRock, and The Vanguard Group. Insiders, including CEO Andrew Rybac...
Investors in Schwälbchen Molkerei Jakob Berz (FRA:SMB) have seen notable returns of 61% over the past five years
By Yahoo! Finance |
2 months ago
Active stock picking aims to outperform the market average by selecting high-performing companies like Schwälbchen Molkerei Jakob Berz, which has shown significant growth. Analyzing underlying fundam...
-
Is Weakness In Schwälbchen Molkerei Jakob Berz AG (FRA:SMB) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
By Yahoo! Finance | 3 months agoSchwälbchen Molkerei Jakob Berz's stock price has dropped 6.0% but its promising financial performance is highlighted by a 19% Return on Equity (ROE)....
-
'Don't mess with people's booze,' Doug Ford says as LBCO strike ends | Watch News Videos Online
By Global News | 3 months agoAfter a two-week strike, the deal between LCBO and its workers' union has been approved, leading to the reopening of stores on Tuesday. Premier Doug Ford expressed his displeasure, emphasizing the imp...
-
Schwälbchen Molkerei Jakob Berz (FRA:SMB) Is Doing The Right Things To Multiply Its Share Price
By Yahoo! Finance | 4 months agoTo identify stocks with potential for long-term value multiplication, look for growing Return on Capital Employed (ROCE) and expanding capital employed....
-
Roche's Columvi shows to offer extended survival in Phase III DLBCL trial
By Yahoo! Finance | 4 months agoRoche's Phase III STARGLO trial showed Columvi with GemOx extended survival in relapsed/refractory DLBCL patients. Results indicated a 41% reduction in mortality risk compared to R-GemOx, meeting prim...
-
EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL
By Yahoo! Finance | 4 months agoRoche's Columvi (glofitamab) showed positive results in the STARGLO trial for relapsed/refractory DLBCL patients. The trial demonstrated improved survival outcomes with potential to compete with other...